MARKET WIREMoomoo • 22h ago
Regentis Biomaterials (RGNT) Stock Forecast & Analyst RatingsMoomoo report covering Regentis Biomaterials Ltd. (RGNT) market action, institutional positioning, and fundamental catalysts.
Why RGNT Stock Traded Steady Today — RQD Quant Desk Flash
$1.37 0.00% NYSE • Live Quote vs Prior Daily Close (Synced Snapshot)
EXT / AFTER-HRS: $1.37
Regentis Biomaterials Ltd. (RGNT) carries a Roarable Rating of E (Strong Sell) with 31/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
ROARABLE E • RED ALERT
Cap $9.6M
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER
Click Any Pre-Computed AI Quant Specialist Briefing on RGNT Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief)
Is RGNT stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼
As of 2026-11-03, Regentis Biomaterials Ltd. (NYSE: RGNT) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 31/100 at a spot price of $1.37 (0.00% 1D, market cap $9.6M). Pillar breakdown: Fundamental Cash Engine 8/20, Institutional 13F & Options Flow 3/20, SEC Balance-Sheet Forensics 10/20, FRED Macro Regime Fit 7/20, and Executive Insider Alignment 3/20. Across 1015 tracked Health Care issuers, RGNT ranks #777 in composite RQD confidence.
✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief)
How does RGNT compare to CLGN and CUPR in the Health Care sector?
▼
Within the Health Care sector (Industrial Specialties), RGNT carries a Roarable E (31/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, CLGN (CollPlant Biotechnologies Ltd) holds a D- grade (41/100 RQD, P/E N/A, ROIC -35.0%, cap $11.9M) and CUPR (Cuprina Holdings (Cayman) Limited (Class A)) posts a E grade (21/100 RQD, P/E N/A, ROIC -35.0%, cap $13.5M). Among the 5-stock peer group, RGNT leads on earnings multiple (N/A) while RGNT leads on capital efficiency (-35.0% ROIC).
✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief)
What are the biggest fundamental strengths and SEC risk factors for RGNT?
▼
Per RGNT's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001912966), Regentis Biomaterials Ltd. generated $19.5M in revenue (+647.6% YoY), -$13.6M in net income, and -$1.4M in free cash flow against $7.6M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.
✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
EXT / AFTER-HRS: $1.37 (-0.19%)🧬 Dilution Drag (+2.48% YoY Shares)⚙️ Cash Engine: 8/20 (D-) • 0% FCF Margin
Verify 90D Bucket Audit →📊 Historical Track Record Warning: Scores below 50 (31/100 · E) historically underperformed SPY in 71% of rolling 90-day windows (-9.4% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →RQD QUANT TACHOMETERRED ALERT • E
3-of-3 JEV AI Jury Bearish Warning
Cash
SEC
Whale
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
5-PILLAR SNOWFLAKE RADARRw E · Rk D-
Each axis scored 0–20
12M PRICE TARGET CONE-12.4% Base Target
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for RGNT)Realized 20D OHLCV Swing Band: ±12.5%
Deterministic 5-Pillar Attribution (31/100 Composite)
🔍 WHY RGNT SCORES 31/100 (E) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: SEC 10-K Forensic Risk+10/20 pts (32% of score)
Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 1/9
▲ #2 Bullish Driver: Cash Engine Quality+8/20 pts (26% of score)
SEC XBRL FY 2025 (10-K): 0% FCF Margin ($0 FCF) & 52% Gross Margin
▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)
Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment
📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)Grade E$1.63-9.8% Next Q
39
Q2 (-2Q)Grade E$1.47-12.2% Next Q
36
Q3 (-1Q)Grade E$1.29+6.2% Next Q
34
CurrentGrade E$1.37-9.4% Hist 90D α
31
Trajectory: E (39) → E (31)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER
⚔️ Adversarial Opposing Case: What Could Spark a RGNT Turnaround Squeeze
While RGNT currently carries a cautious 31/100 (E) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
🚀 Contrarian Squeeze Trigger #1
Established market leader in Health Care with deep daily trading liquidity.
🚀 Contrarian Squeeze Trigger #2
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($1.75) and Max Pain ($1.44) forces dealer call-delta covering toward $16.28.
🚀 Contrarian Squeeze Trigger #3
Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
🎲 LIVE PREDICTION MARKET ODDS TIED TO $RGNT• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “RGNT Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
AUTOMATED RQD QUANT DESK MOVER BRIEFINGFull Market News Desk →
Why RGNT Stock Traded Steady Today — RQD Quant Desk Flash
Regentis Biomaterials Ltd. (RGNT) slipped 0.00% to $1.37, trading at 2% of its 52-week range ($1.23 – $15.5). Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
- ▸Technical Tape: Trading at 2% of its 52-week range ($1.23 – $15.5) with RSI-14 at 38.6 (NEUTRAL RANGE).
- ▸Volatility Profile: Historical 20-day realized swing band of ±12.5% around $1.37 (no active unusual options sweep snapshot on file).
- ▸Fundamental Anchor: Roarable E (Strong Sell) backed by 52% gross margin and $0 annual free cash flow.
Live RGNT Headlines & Catalysts
CATALYSTYahoo Finance • 1d ago
Regentis Biomaterials Reports Strong Surgeon Interest in GelrinC(R) at 8th ICRS Summit in PortugalYahoo Finance report covering Regentis Biomaterials Ltd. (RGNT) market action, institutional positioning, and fundamental catalysts.
MARKET WIREBenzinga • 1d ago
12 Health Care Stocks Moving In Monday's Pre-Market SessionBenzinga report covering Regentis Biomaterials Ltd. (RGNT) market action, institutional positioning, and fundamental catalysts.
MARKET WIREhttps://www.siam.in/ • 1d ago
Regentis Biomaterials (RGNT) Edges Lower: Shares Slip 0.67% to $1.48 - Low Vol Factorhttps://www.siam.in/ report covering Regentis Biomaterials Ltd. (RGNT) market action, institutional positioning, and fundamental catalysts.
MARKET WIREBenzinga • 1d ago
12 Health Care Stocks Moving In Thursday's Intraday SessionBenzinga report covering Regentis Biomaterials Ltd. (RGNT) market action, institutional positioning, and fundamental catalysts.
MARKET WIRETraders Union • 1d ago
Regentis Biomaterials Ltd. (RGNT) Stock Price Prediction for 2026, 2030-2040Traders Union report covering Regentis Biomaterials Ltd. (RGNT) market action, institutional positioning, and fundamental catalysts.
MARKET WIREcitybuzz - • 1d ago
Regentis Biomaterials' GelrinC Shows Promise in Cartilage Repair as Company Eyes FDA Approvalcitybuzz - report covering Regentis Biomaterials Ltd. (RGNT) market action, institutional positioning, and fundamental catalysts.
MARKET WIREMenafn • 1d ago
Regentis Biomaterials (NYSE American: RGNT) To Present At 2026 Thinkequity Conference On Oct. 15Menafn report covering Regentis Biomaterials Ltd. (RGNT) market action, institutional positioning, and fundamental catalysts.
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk
Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring RGNT)
- ✓Walkthrough of RGNT's RQD Radar, SEC cash-conversion gap & downside invalidation levels
- ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
- ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
RGNT // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -46.27%🛡️ HOLDING TREND SUPPORT
2026-11-03O $1.36H $1.37L $1.36C $1.37VOL 24.9K
RES: $2.68SUP: $1.20SMA50: $1.75SMA200: $2.86
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK
RGNT Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure
Share Count & Dilution Monitor
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
Reverse-DCF Expectations Hurdle
8.0%/yr Implied 5Y Growth
vs. +647.6% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
Ellis Vennor Setup Ledger
No active Ellis Vennor swing setup published on RGNT today. View full Setup Ledger →
🦋 Documented & Second-Order Butterfly Connections
Open Graph →
No direct multi-tier Butterfly edges indexed yet for RGNT. Explore sector supply chains on /butterfly.
AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for RGNT today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK
📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (RGNT)
Health Care Rank #777 of 1015
⚔️ CLGN vs RGNT Full Matrix →
1. Head-to-Head Health Care Peer Comparison (RGNT vs. CLGN, CUPR, HSCS, LFWD)
Industry: Industrial Specialties (55 Tracked Issuers)Across 1015 tracked Health Care securities in the Roarable RQD universe, Regentis Biomaterials Ltd. (RGNT) ranks #777 by composite RQD confidence (31/100, grade E) and #896 by equity capitalization ($9.6M). Within this direct 5-issuer industry benchmark cohort, RGNT leads on earnings valuation at N/A trailing P/E, while RGNT leads on capital efficiency and profitability with -35.0% ROIC and — gross margin. CLGN currently holds the highest overall quantitative score in the immediate peer group at 41/100 (D-) compared with RGNT at 31/100 (E).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| RGNT
ACTIVE
Regentis Biomaterials Ltd. | E | 31/100 | — | — | -35.0% | 0.00% | $9.6M | Benchmark Subject |
| CLGN CollPlant Biotechnologies Ltd | D- | 41/100 | — | 64.8% | -35.0% | -1.33% | $11.9M | /clgn-vs-rgnt → |
| CUPR Cuprina Holdings (Cayman) Limited (Class A) | E | 21/100 | — | -1.3% | -35.0% | +3.96% | $13.5M | /cupr-vs-rgnt → |
| HSCS HeartSciences Inc. | D- | 38/100 | — | 59.1% | -35.0% | -9.67% | $16.0M | /hscs-vs-rgnt → |
| LFWD Lifeward Ltd. | E | 32/100 | — | 96.0% | -35.0% | +1.82% | $16.9M | /lfwd-vs-rgnt → |
2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)
SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001912966 ↗In its most recent audited fiscal period (FY2025, filed 2025-12-31), Regentis Biomaterials Ltd. (RGNT) reported GAAP revenue of $19.5M (+647.6% vs. FY2024 revenue of $2.6M , and +260.8% cumulative change since FY2023) , GAAP net income of -$13.6M, operating cash flow of -$1.4M, and free cash flow of -$1.4M (-114.5% YoY). On the balance sheet, RGNT closed FY2025 with $7.6M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 1/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $19.5M | -$13.6M | -$1.4M | -$1.4M | $7.6M | — |
| FY2024 (FY) | 2024-12-31 | $2.6M | $4.8M | -$641.0K | -$641.0K | $482.0K | — |
| FY2023 (FY) | 2023-12-31 | $5.4M | -$4.1M | -$1.2M | -$1.2M | — | — |
3. RGNT Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)
✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLEDIs RGNT stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
As of 2026-11-03, Regentis Biomaterials Ltd. (NYSE: RGNT) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 31/100 at a spot price of $1.37 (0.00% 1D, market cap $9.6M). Pillar breakdown: Fundamental Cash Engine 8/20, Institutional 13F & Options Flow 3/20, SEC Balance-Sheet Forensics 10/20, FRED Macro Regime Fit 7/20, and Executive Insider Alignment 3/20. Across 1015 tracked Health Care issuers, RGNT ranks #777 in composite RQD confidence.
How does RGNT compare to CLGN and CUPR in the Health Care sector?
Within the Health Care sector (Industrial Specialties), RGNT carries a Roarable E (31/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, CLGN (CollPlant Biotechnologies Ltd) holds a D- grade (41/100 RQD, P/E N/A, ROIC -35.0%, cap $11.9M) and CUPR (Cuprina Holdings (Cayman) Limited (Class A)) posts a E grade (21/100 RQD, P/E N/A, ROIC -35.0%, cap $13.5M). Among the 5-stock peer group, RGNT leads on earnings multiple (N/A) while RGNT leads on capital efficiency (-35.0% ROIC).
What are the biggest fundamental strengths and SEC risk factors for RGNT?
Per RGNT's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001912966), Regentis Biomaterials Ltd. generated $19.5M in revenue (+647.6% YoY), -$13.6M in net income, and -$1.4M in free cash flow against $7.6M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.
Where is RGNT trading relative to its 50-day, 200-day, and 52-week technical levels?
RGNT last traded at $1.37 (0.00% on volume of 15,303 shares), positioning the stock -21.71% below its 50-day simple moving average ($1.75) and -52.10% below its 200-day simple moving average ($2.86). Across its 52-week range of $1.23 to $15.50, RGNT sits at the 1.0% percentile with a 14-day RSI of 38.6 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($1.20 to $1.54).
ROARABLE RATING BRIEF • RQD 31/100 (E)
✓ SEC XBRL & RQD VERIFIED
RGNT — Regentis Biomaterials Ltd.: What the Facts Mean to a Prospective Investor
Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2025-12-31
1. Roarable Rating Brief: What This Means to a Prospective Investor
Regentis Biomaterials Ltd. (RGNT) earns a live Roarable RQD composite score of 31/100, corresponding to a E letter grade (Roarable Strong Sell) at a spot price of $1.37 (0.00% 1D, market capitalization $9.6M).
- Fundamental Cash Engine (8/20): Anchored by return on invested capital (ROIC) of -35.0%, gross margin of —, operating margin of —, and free cash flow yield of -14.39%.
- Whale 13F & Options Flow (3/20) + Insider Conviction (3/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
- Macro Regime Fit (7/20) + Forensic Balance Sheet (10/20): Incorporates a 1.00x equity beta, Altman Z-Score of N/A, Piotroski F-Score of 1/9, and Debt/Equity of N/A.
2. Business Model, Unit Margins & SEC Financial Trajectory
Regentis Biomaterials Ltd. (RGNT) is a NYSE-listed issuer classified in the Health Care sector and the Industrial Specialties industry. Reported revenue is — in each period shown in the SEC financials, so the source does not establish how the company generates income. Market capitalization is listed as $9.6M.
In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), Regentis Biomaterials Ltd. (RGNT) reported $19.5M in annual revenue (up from $2.6M in FY2024, +647.6% YoY) and -$13.6M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($5.4M revenue, -$4.1M net income) through FY2025, RGNT scaled operating cash flow to -$1.4M and free cash flow to -$1.4M, backed by $7.6M in total assets against $0 in total debt.
3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff
- 🐂 Primary Bull Case (E • RQD 31/100): Established market leader in Health Care with deep daily trading liquidity. Free cash flow yield of -14.39% and institutional whale pillar of 3/20. With Fundamental Cash Engine at 8/20 and Institutional Whale Flow at 3/20, sustained execution supports upside toward the upper end of the $1.23 – $15.50 52-week range.
- 🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation against — operating margins and a 1.00x macro beta.
4. 2nd-Order Butterfly Ripples & Key Questions to Watch
No upstream suppliers, downstream customers, or sector correlations are identified in the source data. A prospective investor should therefore note that second-order ripple effects cannot be mapped from the available sources; any sector read-through would require information not present here.
- Key Question #1: Can RGNT sustain or expand its — operating margin and -35.0% ROIC against Industrial Specialties peers over the next 4 quarters?
- Key Question #2: Following FY2025 revenue of $19.5M and free cash flow of -$1.4M, how will capital allocation balance growth reinvestment against $0 in total debt?
- Key Question #3: How sensitive is RGNT's equity valuation to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?
RGNT Live News Feed, Press Releases & Catalyst Wire
Real-time company headlines, analyst actions, and sector developments for Regentis Biomaterials Ltd. (RGNT) • Click "Debate This Headline" to argue it in the Roar Pit below
🟡 MARKET WIRE Moomoo • 22h ago
Regentis Biomaterials (RGNT) Stock Forecast & Analyst Ratings Moomoo report covering Regentis Biomaterials Ltd. (RGNT) market action, institutional positioning, and fundamental catalysts.
🟢 CATALYST Yahoo Finance • 1d ago
Regentis Biomaterials Reports Strong Surgeon Interest in GelrinC(R) at 8th ICRS Summit in Portugal Yahoo Finance report covering Regentis Biomaterials Ltd. (RGNT) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Benzinga • 1d ago
12 Health Care Stocks Moving In Monday's Pre-Market Session Benzinga report covering Regentis Biomaterials Ltd. (RGNT) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE https://www.siam.in/ • 1d ago
Regentis Biomaterials (RGNT) Edges Lower: Shares Slip 0.67% to $1.48 - Low Vol Factor https://www.siam.in/ report covering Regentis Biomaterials Ltd. (RGNT) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Benzinga • 1d ago
12 Health Care Stocks Moving In Thursday's Intraday Session Benzinga report covering Regentis Biomaterials Ltd. (RGNT) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Traders Union • 1d ago
Regentis Biomaterials Ltd. (RGNT) Stock Price Prediction for 2026, 2030-2040 Traders Union report covering Regentis Biomaterials Ltd. (RGNT) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE citybuzz - • 1d ago
Regentis Biomaterials' GelrinC Shows Promise in Cartilage Repair as Company Eyes FDA Approval citybuzz - report covering Regentis Biomaterials Ltd. (RGNT) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Menafn • 1d ago
Regentis Biomaterials (NYSE American: RGNT) To Present At 2026 Thinkequity Conference On Oct. 15 Menafn report covering Regentis Biomaterials Ltd. (RGNT) market action, institutional positioning, and fundamental catalysts.
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE
3 Active Posts & Replies
RGNT Bull vs. Bear Conversation Board — What's Your Call at $1.37?
🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON RGNT 🐻 33% BEARISH CONVICTION
DE DeltaGamma_99 RQD DEBATE OPENER • Options Flow Specialist 🐂 BULLISH
🎯 Target: $1.59 (+16.1%)
📌 Pinned Debate Surgeon interest in GelrinC reported at the 8th ICRS Summit gives a possible commercial catalyst, and FY 2024 showed positive net incom
Picked up a starter position in RGNT in my $100K Virtual Cash book at $1.37. Surgeon interest in GelrinC reported at the 8th ICRS Summit gives a possible commercial catalyst, and FY 2024 showed positive net income of $4.8M.. Trading inside a $1.23–$15.50 52-week range with -14.39% FCF yield gives solid downside support if Industrial Specialties multiples expand this quarter.
SectorRotator 🐂 BULL
@DeltaGamma_99 Agree on the RQD 31/100 quality, though with 1.0 beta I'm scaling in with half-size at $1.37 and keeping dry powder in case we test $1.27.
FA FadeTheHype RQD DEBATE OPENER • Contrarian Tape Reader 🐻 BEARISH
🎯 Target: $1.08 (-21.2%)
Spot @ $1.37 ROIC of -35%, FCF yield of -14.39%, and an FY 2025 net loss of -$13.6M with a Piotroski F-Score of 1/9 point to weakening fundamentals.
ROIC of -35%, FCF yield of -14.39%, and an FY 2025 net loss of -$13.6M with a Piotroski F-Score of 1/9 point to weakening fundamentals.. Look at the math on RGNT: paying current EV/EBITDA multiples for -35.0% ROIC and 0.0% operating margins leaves zero margin of safety if Industrial Specialties demand softens. I'd wait for a retest of $1.21 before getting long.